Is it Finally Time to Buy Medical Properties Trust?
Medical Properties Trust (NYSE:MPW) is a REIT that focuses on…
Sell
35
EVH Quote, Financials, Valuation and Earnings
Last price:
$9.59
Seasonality move
:
10%
Day range:
$9.38 - $9.68
52-week range:
$8.35 - $33.63
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.43x
P/B ratio:
1.12x
Volume:
1.4M
Avg. volume:
2.9M
1-year change:
-70.72%
Market cap:
$1.1B
Revenue:
$2.6B
EPS (TTM):
-$0.82
Analysts' Opinion
-
Consensus RatingEvolent Health has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.33, Evolent Health has an estimated upside of 59.72% from its current price of $9.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing -25% downside risk from its current price of $9.60.
Fair Value
-
According to the consensus of 9 analysts, Evolent Health has 59.72% upside to fair value with a price target of $15.33 per share.
EVH vs. S&P 500
-
Over the past 5 trading days, Evolent Health has overperformed the S&P 500 by 1.76% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Evolent Health does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Evolent Health has grown year-over-year revenues for 13 quarters straight. In the most recent quarter Evolent Health reported revenues of $646.5M.
Earnings Growth
-
Evolent Health has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Evolent Health reported earnings per share of -$0.27.
Enterprise value:
1.7B
EV / Invested capital:
1.01x
Price / LTM sales:
0.43x
EV / EBIT:
--
EV / Revenue:
0.66x
PEG ratio (5yr expected):
-0.99x
EV / Free cash flow:
-273.67x
Price / Operating cash flow:
11.17x
Enterprise value / EBITDA:
20.95x
Gross Profit (TTM):
$367.4M
Return On Assets:
-2.4%
Net Income Margin (TTM):
-2.41%
Return On Equity:
-5.92%
Return On Invested Capital:
-3.73%
Operating Margin:
-0.2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1.4B | $2B | $2.6B | $556.1M | $646.5M | |
| Gross Profit | $316.6M | $460.5M | $367.4M | $101.6M | $75.7M | |
| Operating Income | -$19.9M | -$21.1M | -$14.1M | -$9.4M | -$1.3M | |
| EBITDA | $20.7M | -$24.8M | $80.1M | -$6.2M | $12.1M | |
| Diluted EPS | -$0.20 | -$1.27 | -$0.82 | -$0.36 | -$0.27 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $547.6M | $524M | $478.1M | $683.7M | $607.1M | |
| Total Assets | $1.4B | $1.4B | $1.8B | $2.7B | $2.5B | |
| Current Liabilities | $403.3M | $445.5M | $433.4M | $674.2M | $715.5M | |
| Total Liabilities | $752.1M | $725.8M | $957.9M | $1.6B | $1.5B | |
| Total Equity | $619.6M | $693.6M | $859.4M | $1.1B | $1B | |
| Total Debt | $289.9M | $215.7M | $413M | $597M | $662M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$11.6M | $142.6M | $18.8M | $89.4M | -$26.2M | |
| Cash From Investing | -$259.1M | -$415.5M | -$62.9M | -$6.1M | -$19.9M | |
| Cash From Financing | $131.5M | $281.3M | -$565K | -$84.4M | $96.9M | |
| Free Cash Flow | -$49.9M | $113.8M | -$6.1M | $83.3M | -$32.4M | |
EVH
Sector
Market Cap
$1.1B
$36.5M
Price % of 52-Week High
28.55%
44.66%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.9%
1-Year Price Total Return
-70.72%
-39.9%
Beta (5-Year)
1.493
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
-32.59%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$9.67
200-day SMA
Sell
Level
$18.39
Bollinger Bands (100)
Sell
Level
8.17 - 15.29
Chaikin Money Flow
Sell
Level
-29M
20-day SMA
Buy
Level
$9.43
Relative Strength Index (RSI14)
Sell
Level
48.63
ADX Line
Sell
Level
17.06
Williams %R
Neutral
Level
-50.3968
50-day SMA
Sell
Level
$9.85
MACD (12, 26)
Sell
Level
-0.09
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Sell
Level
-4.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.9768)
Sell
CA Score
(Annual)
Level (-0.6247)
Sell
Beneish M-Score
(Annual)
Level (-2.2091)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (1.5027)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
Stock Forecast FAQ
In the current month, EVH has received 8 Buy ratings 1 Hold ratings, and 0 Sell ratings. The EVH average analyst price target in the past 3 months is $15.33.
-
Where Will Evolent Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that Evolent Health share price will rise to $15.33 per share over the next 12 months.
-
What Do Analysts Say About Evolent Health?
Analysts are divided on their view about Evolent Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Evolent Health is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Evolent Health's Price Target?
The price target for Evolent Health over the next 1-year time period is forecast to be $15.33 according to 9 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is EVH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Evolent Health is a Buy. 8 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of EVH?
You can purchase shares of Evolent Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Evolent Health shares.
-
What Is The Evolent Health Share Price Today?
Evolent Health was last trading at $9.59 per share. This represents the most recent stock quote for Evolent Health. Yesterday, Evolent Health closed at $9.60 per share.
-
How To Buy Evolent Health Stock Online?
In order to purchase Evolent Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Signet Jewelers Stock Go Up So Much?
Signet Jewelers (NYSE:SIG) is the largest diamond retailer in the…
Why Did HealthEquity Stock Fall So Much?
HealthEquity (NASDAQ:HQY) is a fintech company that acts as an…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
78
AJINY alert for Mar 29
Ajinomoto [AJINY] is up 99.61% over the past day.
Buy
74
SLNO alert for Mar 29
Soleno Therapeutics [SLNO] is up 6.8% over the past day.
Buy
69
AGX alert for Mar 29
Argan [AGX] is up 19.83% over the past day.
